Racial/ethnic differences in circulating natriuretic peptide levels: The Diabetes Prevention Program
Year: 2020
Type: article
Abstract: Natriuretic peptides are cardiac-derived hormones that enhance insulin sensitivity and reduce fat accumulation. Low natriuretic peptide levels are associated with increased risk of type 2 diabetes mellitus (DM2); a condition with variable prevalence across racial/ethnic groups. Few studies have examined whether circulating natriuretic peptide levels and their response to preventive interventions for DM2 differ by race/ethnicity. The Diabetes Prevention Program (DPP) is a clinical trial (July 31, 1996- July 31, 2001) that randomized participants to preventive interventions for DM2. Using stored serum samples, we examined N-terminus pro-B-type natriuretic peptide (NT-proBNP) levels in 3,220 individuals (56% white; 19% African-American; 15% Hispanic; 5% American-Indian; 5% Asian). The influence of race/ethnicity on NT-proBNP concentrations at baseline and after two years of treatment with placebo, lifestyle, or metformin was examined with multivariable-adjusted regression. At baseline, NT-proBNP differed significantly by race (P < .001), with the lowest values in African-American individuals. Hispanic individuals also had lower baseline NT-proBNP levels compared with whites (P< .001), while NT-proBNP levels were similar between white, American-Indian, and Asian individuals. At two years of follow-up, NT-proBNP levels decreased in African-Americans in each of the DPP study arms, whereas they were stable or increased in the other racial/ethnic groups. In the DPP, African-American individuals had lower circulating NT-proBNP levels compared with individuals in other racial/ethnic groups at baseline and after two years of preventive interventions. Further studies should examine the cardio-metabolic implications of lower natriuretic peptide levels in African-Americans. Trial Registration: ClinicalTrials.gov NCT00004992.
Source: PLoS ONE
Authors: Deepak K. Gupta, Geoffrey A. Walford, Yong Ma, Petr Jarolim, Thomas J. Wang
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,695
Funders: American Diabetes Association, U.S. Department of Veterans Affairs, Bristol-Myers Squibb, Henry M. Jackson Foundation, Vanderbilt University, Merck KGaA, National Institutes of Health, Centers for Disease Control and Prevention, National Institute on Aging, National Heart, Lung, and Blood Institute, National Eye Institute, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Child Health and Human Development, National Center for Research Resources, Office of Research on Women's Health, National Center for Advancing Translational Sciences, National Institute on Minority Health and Health Disparities
Awards: 12/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) - Clinical Center, 6/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) - Clinical Center, Nutriuretic Peptides, the Renin-Angiotensin System, and Metabolic Risk in Obesity, 11/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) - Clinical Center, 8/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) - Clinical Center, G2459644013, 18/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) - Clinical Center, 17/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) - Clinical Center, Development of a Metabolite Signature of Metformin Prevention for Type 2 Diabetes, 4/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) – Clinical Center, 10/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) - Clinical Center, G4822669880, 21/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - One Year Extension - Clinical Center, G5250010382, G5679716143, 7/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) - Clinical Center, 5/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS)–Clinical Center, G6879639498, The Vanderbilt Emergency Medicine Research Training Program (VEMRT), 22/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) – Biostatistics Center, G7557538133, The Vanderbilt Institute for Clinical and Translational Research (VICTR), 3/22 DPPOS Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) – Clinical Center, The natriuretic peptide system in African-Americans, 19/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study-Clinical Center, 2/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) - Clinical Center, 16/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) – Clinical Center, 20/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) – Clinical Center, 15/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) - Clinical Center, G8987501792, Diabetes Research Center
OpenAlex ID: W3008218629